close

March 13, 2025

Crown Bioscience Appoints John Gu as Chief Executive Officer

February 17, 2025

Crown Bioscience Completes Merger with Indivumed Services

February 11, 2025

Crown Bioscience Germany GmbH Achieves Continued CAP 15189:2022 Accreditation

December 11, 2024

Crown Bioscience Wins 2024 Fierce CRO Award for Excellence in Client Service and Partnership

December 10, 2024

Crown Bioscience Wins BioTech Breakthrough Award for Drug Development Innovation

December 12, 2024

Translating In Vitro and In Vivo Multi-Omics Oncology Data to Enhance Early Biomarker Discovery

October 30, 2024

Prostate Cancer Breakthrough: Crown Bioscience Collaborates in €1.75M Eurostars Funded Project for Novel Liquid Biopsy Test

October 1, 2024

Crown Bioscience Expands Singapore Facility with Advanced Oncology Models and Imaging Capabilities

August 21, 2024

Crown Bioscience Partners with CTI to Support Consulting Services in Oncology Drug Development

May 24, 2024

Crown Bioscience Enters Global Agreement with Shanghai Model Organisms Center

May 23, 2024

Innovation Funding and Crown Bioscience: Collaborating to Discover the Next Wave of Oncology Therapies

Contact Us
Biospecimen Request
Databases
CrownLink

US Tel: +1 858 622 2900

UK Tel: +44 870 242 2900

All Contact Information

Our Services
Our Science
About Us
Contact us

Blog

Drug Resistance

Deconstructing Stromal-Tumor Crosstalk in Drug Resistance Mechanisms

11 minute read

Deconstructing Stromal-Tumor Crosstalk in Drug Resistance Mechanisms

March 3, 2025

Mastering the Fight Against Drug Resistance: How to Choose and Use the Right Models

7 minute read

Mastering the Fight Against Drug Resistance: How to Choose and Use the Right Models

January 8, 2025

Combating Cancer Drug Resistance with In Vivo Models

4 minute read

Combating Cancer Drug Resistance with In Vivo Models

December 5, 2024

PARP Inhibitors: Where Are We in 2024 and What’s Coming Next?

4 minute read

PARP Inhibitors: Where Are We in 2024 and What’s Coming Next?

July 18, 2024

Using PDX Models to Tackle Acquired Drug Resistance to Targeted Cancer Therapies

5 minute read

Using PDX Models to Tackle Acquired Drug Resistance to Targeted Cancer Therapies

August 25, 2022

Search our Blog

Categories

About Us

Our Company
Our Purpose
Our Responsibility
Leadership
News & Events

Our Services

Platforms
Target Solutions
Technologies
Service Type

Resources

Blog
Preclinical Models
Publications
Factsheets
White Papers
Ebooks
Webinars

Platforms

OncoExpress™
XenoBase®
MuBase®
HuBase™
OrganoidBase™
CrownLink™

Talk To Us

+1 858 381 3547
Contact Us
Distributors
LinkedIn
X

© 2025 Crown Bioscience. All Rights Reserved.

Privacy Policy | Imprint | Terms of Service | Privacy Preferences

© 2025 Crown Bioscience. All Rights Reserved. Privacy Policy

2025-03-03

2022-12-16